Get the Stockscreener App
28.75
4.39%
-1.32
After Hours:
28.00
-0.75
-2.61%
Viridian Therapeutics Inc stock is traded at $28.75, with a volume of 760.28K.
It is down -4.39% in the last 24 hours and down -11.73% over the past month.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).
See More
Previous Close:
$30.07
Open:
$30.22
24h Volume:
760.28K
Relative Volume:
0.51
Market Cap:
$2.74B
Revenue:
$70.79M
Net Income/Loss:
$-286.89M
P/E Ratio:
-8.1362
EPS:
-3.5336
Net Cash Flow:
$-326.34M
1W Performance:
-1.44%
1M Performance:
-11.73%
6M Performance:
+59.99%
1Y Performance:
+64.57%
1-Day Range:
$28.43
$30.50
1-Week Range:
$28.43
$30.75
52-Week Range:
$9.90
$34.29
Viridian Therapeutics Inc Stock (VRDN) Company Profile
Name
Viridian Therapeutics Inc
Sector
Industry
Phone
617.272.4600
Address
221 CRESCENT STREET, WALTHAM
Compare VRDN vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VRDN
Viridian Therapeutics Inc
|
28.75 | 2.87B | 70.79M | -286.89M | -326.34M | -3.5336 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Viridian Therapeutics Inc Stock (VRDN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-10-25 | Reiterated | Wedbush | Outperform |
| Dec-03-25 | Initiated | William Blair | Outperform |
| Nov-24-25 | Initiated | Truist | Buy |
| Aug-25-25 | Resumed | Jefferies | Buy |
| Dec-19-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Nov-25-24 | Initiated | TD Cowen | Buy |
| Sep-11-24 | Reiterated | Needham | Buy |
| Jun-11-24 | Initiated | Wolfe Research | Outperform |
| Jun-06-24 | Initiated | Goldman | Buy |
| May-09-24 | Downgrade | B. Riley Securities | Buy → Neutral |
| May-09-24 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Jun-14-23 | Initiated | BTIG Research | Buy |
| Jun-14-23 | Resumed | Credit Suisse | Outperform |
| May-30-23 | Initiated | RBC Capital Mkts | Outperform |
| Apr-17-23 | Initiated | Wells Fargo | Overweight |
| Mar-30-23 | Initiated | Stifel | Buy |
| Dec-19-22 | Initiated | Cowen | Outperform |
| Dec-19-22 | Initiated | Needham | Buy |
| Dec-16-22 | Initiated | Credit Suisse | Outperform |
| Dec-01-22 | Initiated | H.C. Wainwright | Buy |
| Jun-23-22 | Initiated | B. Riley Securities | Buy |
| Nov-18-21 | Initiated | SVB Leerink | Outperform |
| Oct-12-21 | Initiated | Evercore ISI | Outperform |
| Jan-25-21 | Initiated | Ladenburg Thalmann | Buy |
View All
Viridian Therapeutics Inc Stock (VRDN) Latest News
Viridian Therapeutics, Inc. (VRDN) Stock Analysis: 42% Potential Upside Amidst Breakthrough Biotechnology Advances - DirectorsTalk Interviews
Street Watch: What are the future prospects of Viridian Therapeutics IncJuly 2025 Catalysts & Expert Curated Trade Setup Alerts - baoquankhu1.vn
How Viridian Therapeutics Inc. (VRDN) Affects Rotational Strategy Timing - Stock Traders Daily
Analysts Offer Insights on Healthcare Companies: Veracyte (VCYT), Sarepta Therapeutics (SRPT) and Viridian Therapeutics (VRDN) - The Globe and Mail
Viridian Therapeutics' (VRDN) Buy Rating Reiterated at Needham & Company LLC - MarketBeat
VRDN: Needham Reiterates Buy Rating with Maintained Price Target - GuruFocus
Performance Recap: Can Alerus Financial Corporation stock outperform in a bear marketMarket Trend Report & Verified Technical Signals - baoquankhu1.vn
Analysts Offer Insights on Healthcare Companies: Alphatec Holdings (ATEC), Viridian Therapeutics (VRDN) and Enovis (ENOV) - The Globe and Mail
Viridian Therapeutics (VRDN) Receives Updated Analyst Rating fro - GuruFocus
Wells Fargo & Company Forecasts Strong Price Appreciation for Viridian Therapeutics (NASDAQ:VRDN) Stock - MarketBeat
Viridian Therapeutics (VRDN) Stock Analysis: Exploring a Promising 26% Upside with Strong Buy Ratings - DirectorsTalk Interviews
Y Intercept Hong Kong Ltd Buys 52,414 Shares of Viridian Therapeutics, Inc. $VRDN - MarketBeat
Analysts Have Conflicting Sentiments on These Healthcare Companies: Intellia Therapeutics (NTLA) and Viridian Therapeutics (VRDN) - The Globe and Mail
Profit Review: Is WEX Inc stock a smart retirement pickJuly 2025 Market Mood & Weekly Consistent Profit Watchlists - baoquankhu1.vn
Viridian Therapeutics, Inc. $VRDN Stock Position Reduced by J. Safra Sarasin Holding AG - MarketBeat
Viridian Therapeutics (NASDAQ:VRDN) Sets New 1-Year HighHere's Why - MarketBeat
Evercore ISI raises Viridian Therapeutics stock price target on subQ TED potential - Investing.com Canada
Viridian Therapeutics, Inc. (VRDN) Investor Outlook: Strong Buy Ratings and 26.51% Potential Upside - DirectorsTalk Interviews
Viridian Therapeutics: Cautious Optimism As Key Milestones Approach (Rating Downgrade) - Seeking Alpha
(VRDN) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Pullback Watch: What are Viridian Therapeutics Incs earnings expectationsJuly 2025 Update & Expert-Curated Trade Recommendations - baoquankhu1.vn
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Evercore Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Cuts Target Price to $44 - 富途资讯
Viridian Therapeutics, Inc.'s (NASDAQ:VRDN) Business Is Trailing The Industry But Its Shares Aren't - 富途资讯
Did FDA Priority Review and EU Push for Thyroid Eye Drug Just Shift Viridian Therapeutics' (VRDN) Investment Narrative? - Sahm
SG Americas Securities LLC Acquires 49,981 Shares of Viridian Therapeutics, Inc. $VRDN - MarketBeat
Viridian Therapeutics stock hits 52-week high at $34.06 By Investing.com - Investing.com Nigeria
Responsive Playbooks and the VRDN Inflection - Stock Traders Daily
Viridian Therapeutics stock jumps to a 52-week high as VRDN traders zero in on June FDA deadline - TechStock²
Viridian Therapeutics (NASDAQ:VRDN) Reaches New 52-Week HighStill a Buy? - MarketBeat
Viridian Therapeutics stock hits 52-week high at $34.06 - Investing.com
Market Review: Is Viridian Therapeutics Inc stock a good pick for beginnersPortfolio Return Report & Capital Efficiency Focused Ideas - baoquankhu1.vn
Viridian Therapeutics, Inc. (VRDN): Growth Potential in Biotechnology with an 81,958% Revenue Surge - DirectorsTalk Interviews
Will Viridian Therapeutics Inc. stock continue upward momentumJuly 2025 Decliners & Real-Time Buy Zone Alerts - Улправда
Viridian Therapeutics (NASDAQ:VRDN) Upgraded by UBS Group to "Strong-Buy" Rating - MarketBeat
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)January 8, 2026 - BioSpace
Assessing Viridian Therapeutics (VRDN) Valuation After FDA Priority Review For Veligrotug - Sahm
What MACD trends signal for Viridian Therapeutics Inc. (1S1) stockPortfolio Performance Report & Expert Curated Trade Setup Alerts - ulpravda.ru
Will Viridian Therapeutics Inc. stock continue dividend increasesJuly 2025 Short Interest & Low Drawdown Trading Techniques - ulpravda.ru
Is Viridian Therapeutics Inc. stock attractive after correctionCPI Data & Technical Entry and Exit Alerts - Улправда
How Viridian Therapeutics Inc. stock compares to market leaders2025 Trading Volume Trends & Expert Approved Momentum Ideas - Улправда
Viridian Therapeutics, Inc.Common Stock (NQ: VRDN - FinancialContent
Why CHRO stock attracts strong analyst attention - Улправда
Can Viridian Therapeutics Inc. stock deliver strong Q4 earningsQuarterly Market Review & Real-Time Chart Pattern Alerts - Улправда
VRDN: Truist Securities Lowers Price Target but Maintains Buy Ra - GuruFocus
Viridian Therapeutics (NASDAQ:VRDN) Price Target Lowered to $40.00 at Truist Financial - MarketBeat
Why Viridian Therapeutics Inc. stock is in analyst buy zonePortfolio Gains Report & Smart Investment Allocation Insights - Улправда
Oklahoma City NewsThe Oklahoman - FinancialContent
UBS Initiates Coverage of Viridian Therapeutics (VRDN) with Buy Recommendation - Nasdaq
Will Viridian Therapeutics Inc. stock deliver consistent dividendsLong-Term Growth Stocks & Turn Market Volatility into Wealth - Улправда
VRDN: UBS Initiates Coverage with a 'Buy' Rating and $50 Price T - GuruFocus
Viridian Therapeutics Inc Stock (VRDN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):